Yours will be better than ours because it is yours. Change a word, say where you live, and stop — ninety seconds is a long call.
I am a constituent and I am asking you to oppose S. 5383. The bill treats synthetic 7-OH differently from natural 7-OH, but they are the same molecule, and no laboratory test can tell a court which one it is looking at. If the concern is novel compounds like MGM-15, assess those on their own evidence. Please do not schedule an alkaloid that kratom and the human body both produce.
Read from the bill's official title and summary only. No text has been published for S. 5383 yet, so unlike every other bill on this site, this reading is not from the text. Treat it as provisional and check the link below.
Amends the Controlled Substances Act to place MGM-15 and MGM-16 in Schedule I.
Schedules synthetic 7-hydroxymitragynine and mitragynine pseudoindoxyl as Schedule I above a specified threshold.
Expands enforcement against manufacturers and distributors of what the bill calls emerging synthetic opioids.
Read twice and referred to the Senate Committee on the Judiciary.
A House companion, H.R. 10272, was introduced on 3 September 2026 with the same title and referred to Energy and Commerce and to the Judiciary. The approach travels; the objection below travels with it.
Draws a line between "synthetic" and "natural" 7-OH - a distinction that does not exist in the finished molecule.
Read the text
No text has been published for this bill yet. That is normal this early, and it is worth knowing: nobody can tell you exactly what it does until there is text to read, ourselves included. The official bill page (opens in a new tab) is where it will appear.
Where we agree with it
Saying this out loud matters. A representative who hears only opposition learns nothing about what we would actually vote for.
That products should be identified accurately, and that a manufacturer selling something other than what the label claims should face enforcement.
What our model act does instead
We are not asking anyone to do nothing. Every objection below comes with the clause we would put in its place — the full text is here.
§3
Definitions
Section 3(d) defines 7-hydroxymitragynine as that molecule in any form - naturally occurring, extracted, concentrated, isolated, synthetic or semi-synthetic. A molecule does not behave differently according to how it was made, and a legal line drawn on origin instead of identity is one that testing cannot verify.
§10
Premarket Review for Novel Kratom Alkaloid Products
MGM-15 and MGM-16 are the case for Section 10, not for Schedule I. Premarket review assesses a genuinely novel alkaloid on evidence before it goes on sale, without also reclassifying the protected alkaloids alongside it.
§13
No Alkaloid Caps; Mandatory Disclosure
A threshold is a cap with a different name. Section 13 requires the concentration to be disclosed and independently verified rather than limited.
Who is behind it
Sponsors are not the enemy and treating them as one wastes the call. They put their name to this because somebody convinced them it would help; the job is to be the person who tells them what it will actually do. If one of them represents you, your call on this bill carries more weight than anyone else's — check whether they do.